Table 1.
Demographics and clinical characteristics of the study population.
| Total (n = 565) | BNT162b2 (n = 305) | mRNA-1273 (n = 260) | |
|---|---|---|---|
| Age at baseline, years [median (IQR)] | 53 (44 – 62) | 54 (43 – 62) | 52 (45 – 61) |
| Sex, n (%) | |||
| Female | 374 (66) | 204 (67) | 170 (65) |
| Male | 191 (34) | 101 (33) | 90 (35) |
| Disease duration at baseline, years [median (IQR)] | 15 (8 – 22) | 14 (8 – 22) | 15 (8 – 21) |
| Evidence of SARS-CoV-2 infection, n (%) | |||
| Past infection | 58 (10) | 30 (10) | 28 (11) |
| No past infection | 507 (90) | 275 (90) | 232 (89) |
| Vaccine, n (%) | |||
| BNT162b2; mRNA-1273 | 305 (54); 260 (46) | 305 (100) | 260 (100) |
| of which one dose* | 4; 7 | 4 | 7 |
| interval between doses [median (IQR)] | 28 (28 – 29) | 28 (28 – 29) | 28 (28 – 29) |
| Diagnosis, n (%) | |||
| Rheumatoid arthritis | 204 (36.1) | 112 (36.7) | 92 (35.4) |
| Axial spondyloarthritis | 207 (36.6) | 107 (35.1) | 100 (38.5) |
| Psoriatic arthritis | 120 (21.2) | 62 (20.3) | 58 (22.3) |
| Undifferentiated arthritis | 34 (6.0) | 24 (7.9) | 10 (3.8) |
| Treatment at baseline, n (%) | |||
| no medication | 84 (14.9) | 42 (13.8) | 42 (16.2) |
| csDMARD | 52 (9.2) | 23 (7.5) | 29 (11.2) |
| of which combination therapy with GC | 4 | 1 | 3 |
| GC monotherapy | 5 (0.9) | 4 (1.3) | 1 (0.4) |
| TNFi | 273 (48.3) | 152 (49.8) | 121 (46.5) |
| of which combination therapy ± , n | 76 | 47 | 29 |
| JAKi | 36 (6.4) | 21 (6.9) | 15 (5.8) |
| of which combination therapy ⊥ , n | 12 | 7 | 5 |
| IL-6/17/23i | 77 (13.6) | 45 (14.8) | 32 (12.3) |
| of which combination therapy ⊥ , n | 20 | 11 | 9 |
| Rituximab | 20 (3.5) | 9 (3.0) | 11 (4.2) |
| of which combination therapy ⊥ , n | 10 | 5 | 5 |
| time since last infusion, days [median (IQR)] | 267 (179 – 568) | 262 (215 – 372) | 286 (142 – 706) |
| Abatacept | 14 (2.5) | 8 (2.6) | 6 (2.3) |
| of which combination therapy ⊥ , n | 6 | 5 | 1 |
| PDE4i | 4 (0.7) | 1 (0.3) | 3 (1.2) |
| of which combination therapy × , n | 1 | - | 1 |
| Total GC use over all patients | |||
|
in mono- and combination therapy, n (%)
Dose, mg [median (IQR)] |
32 (5.7) 5 (2.5 - 7.5) |
20 (6.6) 5 (2.5 - 6) |
12 (4.2) 7.5 (5 – 10) |
*Due to past SARS-CoV-2 infection. No medication, currently on no immunomodulatory medication; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GC, glucocorticoids; TNFi, tumor necrosis factor inhibitor; JAKi, Janus kinase inhibitor; IL-6/17/23i, interleukin 6/17/23 inhibitors; PDE4i, phosphodiesterase-4 inhibitor. ±with csDMARD/GC/csDMARD & GC; ⟂with csDMARD/csDMARD & GC; ×with csDMARD. The 32 patients receiving GCs are double counted, i.e. included in individual treatment groups and the entire GC group, to show the extent of GC use over the entire study population.